Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome

Digestive Diseases and Sciences

Volumn 56, Issue 11, 2011, Pages 3389-3390

  Weinstock, Leonard B ^a,b  

^a Department of Gastroenterology LLC ^*  (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; NALTREXONE; PROBIOTIC AGENT; RIFAXIMIN; TEGASEROD;

BACTERIAL OVERGROWTH; DIARRHEA; FOLLOW UP; HUMAN; IRRITABLE COLON; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REMISSION; RETREATMENT; TREATMENT RESPONSE;

FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; RIFAMYCINS;

EID: 82555194237     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1889-2     Document Type: Letter

References (1)

1. M Pimentel W Morales K Chua, et al. 2011 Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects Dig Dis Sci 56 2067 2072 21559740 10.1007/s10620-011-1728-5 1:CAS:528:DC%2BC3MXntlaisrk%3D